|1.||Nishimura, Yasumasa: 3 articles (06/2008 - 04/2004)|
|2.||Kubota, Nobuo: 2 articles (01/2013 - 09/2005)|
|3.||Sunamura, Makoto: 2 articles (06/2008 - 04/2004)|
|4.||Karasawa, Katsuyuki: 2 articles (06/2008 - 04/2004)|
|5.||Matsuno, Seiki: 2 articles (06/2008 - 04/2004)|
|6.||Nemoto, Kenji: 2 articles (06/2008 - 04/2004)|
|7.||Shibamoto, Yuta: 2 articles (06/2008 - 06/2002)|
|8.||Zhang, Li: 2 articles (01/2007 - 03/2002)|
|9.||Kobayashi, Ataru: 2 articles (09/2005 - 06/2002)|
|10.||Kubota, T: 2 articles (08/2000 - 01/2000)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
06/01/2008 - "Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study."
08/01/2000 - "However, few data have been reported on the radiosensitivity and hypoxic fraction of human pancreatic cancers, and the efficacy of doranidazole against them. "
01/01/2000 - "This study was undertaken to clarify the efficacy and pharmacokinetics of doranidazole in a human pancreatic cancer SUIT-2 xenografted in the pancreas of nude mice. "
04/01/2004 - "A randomized, controlled trial was conducted to clarify the effect of novel radiosensitizer, PR-350, accompanied by intraoperative radiology (IOR) on locally advanced pancreatic cancer. "
03/01/2002 - "In five of seven pancreatic cancer cell lines in which the number of dead cells was determined 5 days after 30 Gy irradiation in the presence of PR-350, the number was significantly increased under hypoxic conditions, but not under aerobic conditions. "
04/01/2004 - "At 6 months following treatment, the tumor mass reduction rate in the PR-350 group was significantly improved (P = 0.0274). "
01/01/2013 - "The BBB in C6-bearing brain was completely disrupted and [(14)C]-doranidazole specifically penetrated the tumor regions. "
01/01/2013 - "T2-weighted MRI was employed to examine the effects of X-irradiation and/or doranidazole on tumor growth. "
09/01/2005 - "It is concluded that the magnitude of radiosensitization of tumors by doranidazole is dependent on the oxygenation status of the tumors and that doranidazole may be useful in increasing the response of hypoxic human pancreatic tumor to IORT."
09/01/2005 - "The relatively well-oxygenated status in MIA PaCa-2 tumor may account for the lack of radiosensitization by doranidazole. "
|3.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
09/01/1999 - "In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer."
09/01/1999 - "PR-350 was an effective hypoxic cell radiosensitizer for a human small cell lung cancer in vivo, in which necrotic change was dominant following irradiation."
|4.||Glioblastoma (Glioblastoma Multiforme)
01/01/2013 - "In the present study, we evaluated the effectiveness of the hypoxic cell sensitizer doranidazole (PR-350) using the C6 rat glioblastoma model, focusing on the status of blood brain barrier (BBB). "
01/01/2013 - "The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption."
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/2007 - "Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002)."
11/01/2007 - "This Phase I/II trial was conducted to assess the efficacy and safety of PR-350, a novel hypoxic cell radiosensitizer, when administered with thoracic radiation therapy (RT) after induction chemotherapy (CT) for locally advanced non-small-cell lung cancer (NSCLC). "
|3.||Eosine Yellowish-(YS) (Eosin)
|4.||Propidium (Propidium Iodide)
|2.||Drug Therapy (Chemotherapy)